Edition:
United Kingdom

Trillium Therapeutics Inc (TRIL.OQ)

TRIL.OQ on NASDAQ Stock Exchange Capital Market

7.55USD
15 Dec 2017
Change (% chg)

$-0.20 (-2.58%)
Prev Close
$7.75
Open
$7.90
Day's High
$8.00
Day's Low
$7.55
Volume
15,004
Avg. Vol
20,656
52-wk High
$13.30
52-wk Low
$4.10

Summary

Name Age Since Current Position

Calvin Stiller

2011 Independent Chairman of the Board

Niclas Stiernholm

2013 President, Chief Executive Officer, Director

James Parsons

2011 Chief Financial Officer

Malik Slassi

Senior Vice President - Discovery Research

Robert Uger

2013 Chief Scientific Officer

Scott Duncan

2013 Director of Intellectual Property

Penka Petrova

2015 Chief Development Officer

Eric Sievers

2015 Chief Medical Officer

Luke Beshar

58 2014 Independent Director

Henry Friesen

79 2011 Independent Director

Robert Kirkman

67 2013 Independent Director

Michael Moore

74 2013 Independent Director

Thomas Reynolds

57 2014 Independent Director

Biographies

Name Description

Calvin Stiller

Dr. Calvin Stiller, M.D., is Independent Chairman of the Board of the Company. Dr. Stiller is the Chair Emeritus of the Ontario Institute for Cancer Research and Professor Emeritus at Western University. Dr. Stiller also sits on the boards of Revera Corporation, Magor Corporation and Smarter Alloys Inc. As an independent director, Dr. Stiller supervises our management and helps to ensure compliance with our corporate governance policies and standards.

Niclas Stiernholm

Dr. Niclas Stiernholm is President, Chief Executive Officer, Director of the Company. Dr. Stiernholm is the President and Chief Executive Officer of Trillium since April 9, 2013 and was the President and Chief Executive Officer of Trillium Privateco since 2002. He joined Trillium from YM BioSciences Inc. where he was Executive Vice President and Chief Scientific Officer. Dr. Stiernholm also sits on the board of Vasomune Therapeutics Inc. As President and Chief Executive Officer, Dr. Stiernholm is responsible for overseeing our strategic direction, executing business development plans and ensuring that our scientific programs remain funded and advance on schedule. As a director, Dr. Stiernholm participates in management oversight and helps to ensure compliance with our corporate governance policies and standards.

James Parsons

Mr. James T. Parsons, CPA, is Chief Financial Officer of the Company. Mr. Parsons is the Chief Financial Officer of Trillium since August 25, 2011 and was also the Director, Finance of Trillium Privateco. He was previously the Vice President, Finance of DiaMedica Inc. from October 2010 to May 2014, and Chief Financial Officer of Amorfix Life Sciences Ltd. from 2006 to 2010. Mr. Parsons sits on the board of Sernova Corp and DiaMedica Inc.

Malik Slassi

Robert Uger

Scott Duncan

Penka Petrova

Dr. Penka Petrova is Chief Development Officer of the Company. She was the Vice President, Drug Development from April 2013 to May 2015. Dr. Petrova joined Trillium Privateco from Prescient Neuropharma in 2003. As Chief Development Officer, Dr. Petrova is responsible for managing our formal drug development efforts, including all outsourced activities to contract manufacturers and contract research organizations.

Eric Sievers

Mr. Eric Sievers is Chief Medical Officer of the Company. He previously held several senior roles at Seattle Genetics including the Senior Vice President, Clinical Development from October 2013 to March 2015, the Vice President and Interim Chief Medical Officer from 2012 to October 2013, and Vice President, Clinical Affairs from 2011 to 2012, and Executive Medical Director from 2010 to 2011. As Chief Medical Officer, Dr. Sievers is responsible for the design and execution of our clinical and regulatory strategy.

Luke Beshar

Mr. Luke M. Beshar, CPA, is Independent Director of the Company. Mr. Beshar is an independent biotechnology consultant and financial expert. He was most recently the Executive/Senior Vice President and Chief Financial Officer of NPS Pharmaceuticals, Inc., a global biopharmaceutical company from November 2007 to February 2015. Mr. Beshar also sits on the boards of REGENXBIO Inc., Entera Bio Ltd. and Sancilio Pharmaceuticals Company, Inc.

Henry Friesen

Dr. Henry Friesen, M.D. is Independent Director of the Company. Dr. Friesen is a Distinguished University Professor Emeritus at University of Manitoba since October 2000. As an independent director, Dr. Friesen supervises our management and helps to ensure compliance with our corporate governance policies and standards.

Robert Kirkman

Dr. Robert L. Kirkman is an Independent Director of the Company. Dr. Kirkman was the President and Chief Executive Officer and director of Oncothyreon Inc., an oncology-focused biotechnology company from September 2006 to January 2016. As an independent director, Dr. Kirkman supervises our management and helps to ensure compliance with our corporate governance policies and standards.

Michael Moore

Dr. Michael Moore, Ph.D., is Independent Director of the Company. Dr. Moore is the Chair of MISSION Therapeutics Ltd. since 2012 and a board chair or director of PsiOxus Therapeutics Ltd., Chronos Therapeutics Ltd. and Akinion Pharmaceuticals AB. From 2004 to 2013, Dr. Moore was the Chair of Trillium Privateco, and from 2003 to 2008, Dr. Moore was the Chief Executive Officer and director of PIramed Ltd, a UK- based oncology company sold to Roche in 2008. As an independent director, Dr. Moore supervises our management and helps to ensure compliance with our corporate governance policies and standards.

Thomas Reynolds

Dr. Thomas C. Reynolds, M.D. Ph.D. is Independent Director of the Company. Dr. Reynolds is an independent biotechnology consultant since February 2013, and was Chief Medical Officer of Seattle Genetics, Inc., a biotechnology company focused on antibody-based therapies for the treatment of cancer from March 2007 to January 2013. Dr. Reynolds also sits on the boards of MEI Pharma, Inc. and Oxford Biotherapeutics, Ltd. As an independent director, Dr. Reynolds supervises our management and helps to ensure compliance with our corporate governance policies and standards.

Basic Compensation